The prevalence of alcoholic liver disease and non-alcoholic liver disease patients has nearly doubled over the past decades worldwide. Alcoholic liver disease among patients with chronic liver disease has increased with arisen due to alcohol consumption and obesity. The diagnosis plays a crucial role in treating such conditions based on the stages of liver functioning. The elevated liver enzymes are the key characterizing of identifying the alcoholic liver disease (ALD) and NAFLD. Later on, there is a progression of the disease conditions by developing fibrosis and cirrhosis, leading to liver carcinoma. The other state, steatohepatitis, is associated with an increase in liver-related and can lead to mortality. Risk factors for both diseases are growing, leading to various complications in health. There is no specific treatment up to date for these conditions, but statins play a crucial role in managing several liver disease conditions. The commonly used drug is hydroxymethylglutaryl coenzyme A (HMG Co-A) reductase inhibitors. It is also known as statins, which help normalize liver enzymes in patients with elevated plasma aminotransferases. As a result, external liver damage is considered safe for the liver as the Statin medication at low to moderate dose usage. OBJECTIVES: The main scope of this review is to study the various factors like pharmacological actions, adverse events, and biochemical and liver cell imaging results in patients with ALD and NAFLD. The different types of statins used in alcoholic and non-alcoholic patients’ clinical data for the safety of the statin therapy were concluded in this review. Fatty liver changes of both liver disease conditions were studied using different drugs. The other liver enzymes like Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl Transferase (GGT), and the effectiveness of Statin therapy are considered vital concepts in this review.
Bhardwaj, S.S. and Chalasani, N. (2007) Lipid-Lowering Agents that Cause Drug-Induced Hepatotoxicity. Clinics in Liver Disease, 11, 597-613. https://doi.org/10.1016/j.cld.2007.06.010
Omagari, K., Kadokawa, Y., Masuda, J., Egawa, I., Sawa, T., Hazama, H., et al. (2002) Fatty Liver in Non-Alcoholic-Overweight Japanese Adults: Incidence and Clinical Characteristics. Journal of Gastroenterology and Hepatology, 17, 1098-1105. https://doi.org/10.1046/j.1440-1746.2002.02846.x
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. (2008) Genetic Variation in PNPLA3 Confers Susceptibility to Non-Alcoholic Fatty Liver Disease. Nature Genetics, 40, 1461-1465. https://doi.org/10.1038/ng.257
Thurman, R.G. (1998) Mechanisms of Hepatic Toxicity. II. The Alcoholic Liver Injury Involves the Activation of Kupffer Cells by the Endotoxin. American Journal of Physiology, 275, G605-G611. https://doi.org/10.1152/ajpgi.1998.275.4.G605
Loomba, R. and Sanyal, A.J. (2013) The Global NAFLD Epidemic. Nature Reviews Gastroenterology & Hepatology, 10, 686-690. https://doi.org/10.1038/nrgastro.2013.171
Struben, V.M., Hespenheide, E.E. and Caldwell, S.H. (2000) Non-Alcoholic Steatohepatitis and Cryptogenic Cirrhosis in Kindreds. The American Journal of Medicine, 108, 9-13. https://doi.org/10.1016/S0002-9343(99)00315-0
Violi, F., Calvieri, C. and Ferro, D. (2013) Statins as Antithrombotic Drugs. Circulation, 127, 251-257. https://doi.org/10.1161/CIRCULATIONAHA.112.145334
Pelli, N., Setti, M., Ceppa, P., Toncini, C. and Indiveri, F. (2003) Autoimmune Hepatitis Revealed by Atorvastatin. European Journal of Gastroenterology & Hepatology, 15, 921-924. https://doi.org/10.1097/00042737-200308000-00014
Caldwell, S.H., Zaidman, J.S. and Hespenheide, E.E. (2003) The Liver and Statin Drug Therapy: Uncertain Navigation in the Sea of Risk-Benefits. Pharmacoepidemiology and Drug Safety, 12, 303-306. https://doi.org/10.1002/pds.833
Ma, P.T., Gil, G., Sudhof, T.C., Bilheimer, D.W., Goldstein, J.L. and Brown, M.S. (1986) Mevinolin, an Inhibitor of Cholesterol Synthesis, Induces mRNA for Low-Density Lipoprotein Receptor in Livers of Hamsters and Rabbits. Proceedings of the National Academy of Sciences of the United States of America, 83, 8370-8374. https://doi.org/10.1073/pnas.83.21.8370
Rehm, J., Taylor, B., Mohapatra, S., Irving, H., Baliunas, D. and Patra, J. (2010) Alcohol as a Risk Factor for Liver Cirrhosis: A Systematic Review and Meta-Analysis. Drug and Alcohol Review, 29, 437-445. https://doi.org/10.1111/j.1465-3362.2009.00153.x
Shieh, K., Gilchrist, J.M. and Promrat, K. (2010) Frequency, and Predictors of Non-Alcoholic Fatty Liver Disease in the Myotonic Dystrophy. Muscle & Nerve, 41, 197-201. https://doi.org/10.1002/mus.21484
Angulo, P. (2002) Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 346, 1221-1231. https://doi.org/10.1056/NEJMra011775
Daniel, S., Ben-Menachem, T., Vasudevan, G., Ma, C.K. and Blumenkehl, M. (1999) Prospective Evaluation of Unexplained Chronic Liver Transaminase Abnormalities in Asymptomatic and Symptomatic Patients. American Journal of Gastroenterology, 94, 3010-3014. https://doi.org/10.1111/j.1572-0241.1999.01451.x
de Castro, M.L., Hermo, J.A. and Baz, A. (2006) Acute Cholestatic Hepatitis after Atorvastatin Reintroduction. Gastroenterología y Hepatología, 29, 21-24. https://doi.org/10.1157/13083248
Patti, G., Cannon, C.P., Murphy, S.A., Mega, S., Pasceri, V., Briguori, C., et al. (2011) Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies. Circulation, 123, 1622-1632. https://doi.org/10.1161/CIRCULATIONAHA.110.002451
Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H., Burke, M., Davey Smith, G., et al. (2013) Statins for the Primary Prevention of Cardiovascular Disease. Cochrane Database of Systematic Reviews, 2013, CD004816. https://doi.org/10.1002/14651858.CD004816.pub5
Fallo, F., Dalla Pozza, A. and Tecchio, M. (2010) Non-Alcoholic Fatty Liver Disease in Primary Aldosteronism: A Pilot Study. American Journal of Hypertension, 23, 2-5. https://doi.org/10.1038/ajh.2009.206
Adachi, Y., Bradford, B.U., Gao, W., Bojes, H.K. and Thurman, R.G. (1994) The Activation of Kupffer Cells Prevents Early Alcohol-Induced Liver Injury. Hepatology, 20, 453-460. https://doi.org/10.1002/hep.1840200227
Adachi, Y., Moore, L.E., Bradford, B.U., Gao, W. and Thurman, R.G. (1995) Antibiotics Prevent Liver Injury in Rats Following Long-Term Exposure to Ethanol. Gastroenterology, 108, 218-224. https://doi.org/10.1016/0016-5085(95)90027-6
Tilg, H., Jalan, R., Kaser, A., Davies, N.A., Offner, F.A., Hodges, S.J., et al. (2003) Anti-Tumor Necrosis Factor-Alpha Monoclonal Antibody Therapy in Severe Alcoholic Hepatitis. Journal of Hepatology, 38, 419-425. https://doi.org/10.1016/S0168-8278(02)00442-7
Hashimoto, E., Yatsuji, S., Kaneda, H., Yoshioka, Y., Taniai, M., Tokushige, K., et al. (2005) The Characteristics and Natural History of Japanese Patients with Non-Alcoholic Fatty Liver Disease. Hepatology Research, 33, 72-76.
Hritz, I., Mandrekar, P., Velayudham, A., Catalano, D., Dolganiuc, A., Kodys, K., et al. (2008) The Critical Role of Toll-Like Receptor (TLR) 4 in Alcoholic Liver Disease Is Independent of the Standard TLR Adapter MyD88. Hepatology, 48, 1224-1231. https://doi.org/10.1002/hep.22470
Mandrekar, P. and Szabo, G. (2009) Signaling Pathways in Alcohol-Induced Liver Inflammation. Journal of Hepatology, 50, 1258-1266. https://doi.org/10.1016/j.jhep.2009.03.007
Wolters, L.M.M and Van Buuren, H.R. (2005) Rosuvastatin-Associated Hepatitis with Autoimmune Features. European Journal of Gastroenterology and Hepatology, 17, 589-590. https://doi.org/10.1097/00042737-200505000-00019
Nakad, A., Bataille, L., Hamoir, V., Sempoux, C. and Horsmans, Y. (1999) Atorvastatin-Induced Acute Hepatitis with No Cross-Toxicity with the Simvastatin. Lancet, 353, 1763-1764. https://doi.org/10.1016/S0140-6736(99)00569-3
Vernon, G., Baranova, A. and Younossi, Z.M. (2011) Systematic Review: The Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in Adults. Alimentary Pharmacology and Therapeutics, 34, 274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
Karlmark, K.R., Wasmuth, H.E., Trautwein, C. and Tacke, F. (2008) Chemokine-Directed Immune Cell Infiltration in Acute and Chronic Liver Disease. Expert Revue of Gastroenterology & Hepatology, 2, 233-242. https://doi.org/10.1586/17474124.2.2.233
Seki, E., de Minicis, S., Inokuchi, S., Taura, K., Miyai, K., van Rooijen, N., et al. (2009) CCR2 Promotes Hepatic Fibrosis in Mice. Hepatology, 185, 185-197. https://doi.org/10.1002/hep.22952
Sheng, Z., Otani, H., Brown, M.S. and Goldstein, J.L. (1995) Independent Regulation of Sterol Regulatory Element-Binding Proteins 1 and 2 in Hamster Liver. Proceedings of the National Academy of Sciences of the United States of America, 92, 935-938. https://doi.org/10.1073/pnas.92.4.935
Amarapurkar, D., Kamani, P., Patel, N., Gupte, P., Kumar, P., Agal, S., et al. (2007) Prevalence of Non-Alcoholic Fatty Liver Disease: A Population-Based Study. Annals of Hepatology, 6, 161-163. https://doi.org/10.1016/S1665-2681(19)31922-2
Li, H., Wang, Y.J., Tan, K., Zeng, L., Liu, L., Liu, F.J., et al. (2009) Prevalence and Risk Factors of Fatty Liver Disease in Chengdu, Southwest China. Hepatobiliary & Pancreatic Diseases International, 8, 377-382.
Pasternak, R.C., Smith Jr., S.C., Bairey-Merz, C.N., Grundy, S.M., Cleeman, J.I. and Lenfant, C. (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 106, 1024-1028. https://doi.org/10.1161/01.CIR.0000032466.44170.44
Frith, J., Day, C.P., Henderson, E., Burt, A.D. and Newton, J.L. (2009) Non-Alcoholic Fatty Liver Disease in Older People. Gerontology, 55, 607-613. https://doi.org/10.1159/000235677
Kagansky, N., Levy, S., Keter, D., Rimon, E., Taiba, Z., Fridman, Z., et al. (2004) Non-Alcoholic Fatty Liver Disease—A Common and Benign Finding in Octogenarian Patients. Liver International, 24, 588-594. https://doi.org/10.1111/j.1478-3231.2004.0969.x
Kichian, K., McLean, R., Gramlich, L.M., Bailey, R.J. and Bain, V.G. (2003) Non-Alcoholic Fatty Liver Disease in Patients Investigated for Elevated Liver Enzymes. Canadian Journal of Gastroenterology and Hepatology, 17, Article ID: 268528. https://doi.org/10.1155/2003/268528
Park, S.H., Jeon, W.K.., Kim, S.H., Kim, H.J., Park, D.I., Cho, Y.K., et al. (2006) Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease among Korean Adults. Journal of Gastroenterology and Hepatology, 21, 138-143. https://doi.org/10.1111/j.1440-1746.2005.04086.x
Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. (2005) The Natural History of Non-Alcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology, 129, 113-121. https://doi.org/10.1053/j.gastro.2005.04.014
Askgaard, G., Gronbaek, M., Kjaer, M.S., Tjonneland, A. and Tolstrup, J.S. (2015) Alcohol Drinking Pattern and Risk of Alcoholic Liver Cirrhosis: A Prospective Cohort study. Journal of Hepatology, 62, 1061-1067. https://doi.org/10.1016/j.jhep.2014.12.005
Ascha, M.S., Hanouneh, I.A., Lopez, R., Tamimi, T.A., Feldstein, A.F. and Zein, N.N. (2010) The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Non-Alcoholic Steatohepatitis. Hepatology, 51, 1972-1978. https://doi.org/10.1002/hep.23527
Hashimoto, E., Yatsuji, S., Tobari, M., Taniai, M., Torii, N., Tokushige, K., et al. (2009) Hepatocellular Carcinoma in Patients with Non-Alcoholic Steatohepatitis. Journal of Gastroenterology, 44, 89-95. https://doi.org/10.1007/s00535-008-2262-x
Lee, J.Y., Kim, K.M. and Lee, S.G. (2007) Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Potential Living Liver Donors in Korea: A Review of 589 Consecutive Liver Biopsies in a Single Center. Journal of Hepatology, 47, 239-244. https://doi.org/10.1016/j.jhep.2007.02.007
Goldstein, J.L. and Brown, M.S. (2015) A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 161, 161-172. https://doi.org/10.1016/j.cell.2015.01.036
Leite, N.C., Salles, G.F., Araujo, A.L., Villela-Nogueira, C.A. and Cardoso, C.R. (2009) Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Liver International, 29, 113-119. https://doi.org/10.1111/j.1478-3231.2008.01718.x
Seki, E., De Minicis, S., Gwak, G.Y., Kluwe, J., Inokuchi, S., Bursill, C.A., et al. (2009) CCR1 and CCR5 Promote Hepatic Fibrosis in Mice. Journal of Clinical Investigation, 119, 1858-1870. https://doi.org/10.1172/JCI37444
Szabo, G. and Dolganiuc, A. (2006) Mandrekar Pattern Recognition Receptors: A Contemporary View on Liver Diseases. Hepatology, 44, 287-298. https://doi.org/10.1002/hep.21308
Donohue Jr., T.M., Osna, N.A., Trambly, C.S., Whitaker, N.P., Thomes, P.G., Todero, S.L., et al. (2012) Early Growth Response-1 Contributes to Steatosis Development after Acute Ethanol Administration. Alcoholism: Clinical and Experimental Research, 36, 759-767. https://doi.org/10.1111/j.1530-0277.2011.01681.x
Ruhl, C.E. and Everhart, J.E. (2005) Joint Effects of Body Weight and Alcohol on Elevated Serum Alanine Aminotransferase in the United States Population. Clinical Gastroenterology and Hepatology, 3, 1260-1268. https://doi.org/10.1016/S1542-3565(05)00743-3
Kotronen, A., Johansson, L.E., Johansson, L.M., Roos, C., Westerbacka, J., Hamsten, A., et al. (2009) A Common Variant in PNPLA3, Which Encodes Adiponutrin, Is Associated with Liver Fat Content in Humans. Diabetologia, 52, 1056-1060. https://doi.org/10.1007/s00125-009-1285-z
Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., et al. (2010) Pioglitazone, Vitamin E or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine, 362, 1675-1685. https://doi.org/10.1056/NEJMoa0907929
Fan, J.G., Zhu, J., Li, X.J., Chen, L., Li, L., Dai, F., et al. (2005) Prevalence of and Risk Factors for Fatty Liver in a General Population of Shanghai, China. Journal of Hepatology, 43, 508-514. https://doi.org/10.1016/j.jhep.2005.02.042
Kim, H.J., Kim, H.J., Lee, K.E., Kim, D.J., Kim, S.K., Ahn, C.W., et al. (2004) Metabolic Significance of Non-Alcoholic Fatty Liver Disease in Nonobese, Nondiabetic Adults. Archives of Internal Medicine, 164, 2169-2175. https://doi.org/10.1001/archinte.164.19.2169
Ong, J.P., Pitts, A. and Younossi, Z.M. (2008) Increased Mortality and Liver-Related Mortality in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 49, 608-612. https://doi.org/10.1016/j.jhep.2008.06.018
Sookoian, S. and Priola, C.J. (2011) Meta-Analysis of the Influence of the I148M Variant of Patatin-Like Phospholipase Domain-Containing Three-Gene (PNPLA3) on the Susceptibility and Histological Severity of the Non-Alcoholic Fatty Liver Disease. Hepatology, 53, 1883-1894. https://doi.org/10.1002/hep.24283
Chen, Z.W., Chen, L.Y., Dai, H.L., Chen, J.H. and Fang, L.Z. (2008) Relation between Alanine Aminotransferase Levels and Metabolic Syndrome in Non-Alcoholic Fatty Liver Disease. Journal of Zhejiang University SCIENCE B, 9, Article No. 616. https://doi.org/10.1631/jzus.B0720016
Souza, M.R., DinizMde, F., Medeiros-Filho, J.E. and Trigueiro de Araújo, M.S. (2012) Metabolic Syndrome and Risk Factors for Non-Alcoholic Fatty Liver Disease. Arquivos de Gastroenterologia, 49, 89-96. https://doi.org/10.1590/S0004-28032012000100015
Kariv, R., Leshno, M., Beth-Or, A., Strul, H., Blendis, L., Kokia, E., et al. (2006) Reevaluation of Serum Alanine Amino-Transferase Normal Upper Limits and Modulating Factors in a Large-Scale Population Study. Liver International, 26, 445-450. https://doi.org/10.1111/j.1478-3231.2006.01197.x
Prashanth, M., Ganesh, H.K. and Vima, M.V. (2009) Prevalence of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Journal of the Association of Physicians of India, 57, 205-210.
Frazier, T.H., Stocker, A.M., Kershner, N.A., Marsano, L.S. and McClain, C.J. (2011) Treatment of Alcoholic Liver Disease. Therapeutic Advances in Gastroenterology, 4, 63-81. https://doi.org/10.1177/1756283X10378925
Schierwagen, R., Maybüchen, L., Zimmer, S., Hittatiya, K., B?ck, C., Klein, S., et al. (2015) Seven Weeks of Western diet in Apolipoprotein-E-Deficient Mice Induce Metabolic Syndrome and Non-Alcoholic Steatohepatitis with Liver Fibrosis. Scientific Reports, 5, Article No. 12931. https://doi.org/10.1038/srep12931
Baranova, A., Tran, T.P., Birerdinc, A. and Younossi, Z.M. (2011) Systematic Review: Association of Polycystic Ovary Syndrome with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 33, 801-814. https://doi.org/10.1111/j.1365-2036.2011.04579.x
Gambarin-Gelwan, M., Kinkhabwala, S.V., Schiano, T.D., Bodian, C., Yeh, H.C. and Fut-Terweit, W. (2007) Prevalence of Non-Alcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. Clinical Gastroenterology and Hepatology, 5, 496-501. https://doi.org/10.1016/j.cgh.2006.10.010
Cerda, C., Pérez-Ayuso, R.M. and Riquelme, A. (2007) Non-Alcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. Journal of Hepatology, 47, 412-417. https://doi.org/10.1016/j.jhep.2007.04.012
Hossain, N., Stepanova, M., Afendy, A., Nader, F., Younossi, Y., Rafiq, N., et al. (2011) Non-Alcoholic Steatohepatitis (NASH) Patients with the Polycystic Ovarian Syndrome (PCOS). Scandinavian Journal of Gastroenterology 46, 479-484. https://doi.org/10.3109/00365521.2010.539251
Crum-Cianflone, N, Dilay, A., Collins, G., Asher, D., Campin, R., Medina, S., et al. (2009) Non-Alcoholic Fatty Liver Disease among HIV-Infected Persons. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50, 464-473. https://doi.org/10.1097/QAI.0b013e318198a88a
Wrenn, K.D. and Slovis, C.M. (1992) Is Intravenous Thiamine Safe? The American Journal of Emergency Medicine, 10, 165. https://doi.org/10.1016/0735-6757(92)90054-2
Guaraldi, G., Squillace, N.., Stentarelli, C., Orlando, G., D’Amico, R., Ligabue, G., et al. (2008) Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. Clinical Infectious Diseases, 47, 250-257. https://doi.org/10.1086/589294
Teli, M.R., Day, C.P, Burt, A.D. and Bennett, M.K. (1995) Determinants of Progression to Cirrhosis or Fibrosis in Pure Alcoholic Fatty Liver. Lancet, 346, 987-990. https://doi.org/10.1016/S0140-6736(95)91685-7
Singal, A.K., Chaha, K.S., Rasheed, K. and Anand, B.S. (2013) Liver Transplantation in Alcoholic Liver Disease Current Status and Controversies. World Journal of Gastroenterology, 19, 5953-5963. https://doi.org/10.3748/wjg.v19.i36.5953
Zakhari, S. and Li, T.K. (2007) Determinants of Alcohol Use and Abuse: Impact of Quantity and Frequency Patterns on Liver Disease. Hepatology, 46, 2032-2039. https://doi.org/10.1002/hep.22010
Jimenez-Alonso, J., Osorio, J.M., Gutierrez-Cabello, F., López de la Osa, A., León, L. and Mediavilla García, J.D. (1999) Atorvastatin-Induced Cholestatic Hepatitis in a Young Woman with Systemic Lupus Erythematosus. Grupo Lupus Virgen de las Nieves. Archives of Internal Medicine, 159, 1811-1812.
Lefkowitch, J.H. (2005) Morphology of Alcoholic Liver Disease. Clinics in Liver Disease, 9, 37-53. https://doi.org/10.1016/j.cld.2004.11.001
Yu, A.S. and Keeffe, E.B. (2003) Elevated AST or ALT to Non-Alcoholic Fatty Liver Disease: An Accurate Predictor of Disease Prevalence? American Journal of Gastroenterology, 98, 955-956. https://doi.org/10.1111/j.1572-0241.2003.07485.x
Chong, L.-W., Hsu, Y.-C., Lee, T.-F., Lin, Y., Chiu, Y.T., Yang, K.C., et al. (2015) Fluvastatin Attenuates Hepatic Steatosis-Induced Fibrogenesis in Rats through Inhibiting Paracrine Effect of Hepatocyte on Hepatic Stellate Cells. BMC Gastroenterology, 15, Article No. 22. https://doi.org/10.1186/s12876-015-0248-8
Marrone, G., Russo, L., Rosado, E., Hide D, García-Carde?a, G., García-Pagán, J.C., et al. (2013) The Transcription Factor KLF2 Mediates Hepatic Endothelial Protection and Paracrine Endothelial-Stellate Cell Deactivation Induced by Statins. Journal of Hepatology, 58, 98-103. https://doi.org/10.1016/j.jhep.2012.08.026
Chang, C.Y. and Schiano, T.D. (2007) Revue Article: Drug Hepatotoxicity. Alimentary Pharmacology and Therapeutics, 25, 1135-1151. https://doi.org/10.1111/j.1365-2036.2007.03307.x
Dujovne, C.A. (2002) Side Effects of Statins: Hepatitis versus “Transaminitis”-Myositis versus “CPKitis”. American Journal of Cardiology, 89, 1411-1413. https://doi.org/10.1016/S0002-9149(02)02356-1
Alla, V., Abraham, J., Siddiqui, J., Raina, D., Wu, G.Y., Chalasani, N.P., et al. (2006) Autoimmune Hepatitis Triggered by Statins. Journal of Clinical Gastroenterology, 40, 757-761. https://doi.org/10.1097/00004836-200609000-00018
Graziadei, I.W., Obermoser, G.E., Sepp, N.T., Erhart, K.H. and Vogel, W. (2003) Drug-Induced, a Lupus-Like Syndrome Associated with Severe Autoimmune Hepatitis. Lupus, 12, 409-412. https://doi.org/10.1191/0961203303lu313cr
Pignatelli, P., Carnevale, R., Pastori, D., Cangemi, R., Napoleone, L., Bartimoccia, S., et al. (2012) Immediate Antioxidant, and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2. Circulation, 126, 92-103. https://doi.org/10.1161/CIRCULATIONAHA.112.095554
Becker, U., Deis, A., Sorensen, T.I.A., Gronbaek, M., Borch-Johnsen, K., Muller, C.F., et al. (1996) Prediction of Risk of Liver Disease by Alcohol Intake, Sex, and Age: A Prospective Population Study. Hepatology, 23, 1025-1029. https://doi.org/10.1002/hep.510230513
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y. and Patra, J. (2009) Global Burden of Disease and Injury and Economic Cost Attributable to Alcohol Use and Alcohol-Use Disorders. Lancet, 373, 2223-2233. https://doi.org/10.1016/S0140-6736(09)60746-7
Galli, A., Pinaire, J., Fischer, M., Dorris, R. and Crabb, D.W. (2001) The Transcriptional and DNA Binding Activity of Peroxisome Proliferator-Activated Receptor Alpha Is Inhibited by Ethanol Metabolism: A Novel Mechanism for the Development of Ethanol-Induced Fatty Liver. Journal of Biological Chemistry, 276, 68-75. https://doi.org/10.1074/jbc.M008791200
McClain, C.J., Song, Z., Barve, S.S., Hill, D.B. and Deaciuc, I. (2004) Recent Advances in Alcoholic Liver Disease: IV. Dysregulated Cytokine Metabolism in Alcoholic Liver Disease. American Journal of Physiology-Gastrointestinal and Liver Physiology, 287, G497-G502. https://doi.org/10.1152/ajpgi.00171.2004
Bellentani, S. and Tiribelli, C. (2001) The Spectrum of Liver Disease in the General Population: Lesson from the Dionysos Study. Journal of Hepatology, 35, 531-537. https://doi.org/10.1016/S0168-8278(01)00151-9
Wilfred de Alwis, N.M. and Day, C.P. (2007) Genetics of Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 27, 44-54. https://doi.org/10.1055/s-2006-960170
Grove, J., Brown, A.S., Daly, A.K., James, O., Day, C.P. and Brown, A. (1998) The RSAI Polymorphism of CYP2E1 and Susceptibility to Alcoholic Liver Disease in Caucasians: Effect on Age of Presentation and Dependence on Alcohol Dehydrogenase Genotype. Pharmacogenetics, 8, 335-342. https://doi.org/10.1097/00008571-199808000-00007
Bays, H., Cohen, D.E., Chalasani, N. and Harrison, S.A. (2014) An Assessment by the Statin Liver Safety Task Force: 2014 Update. Journal of Clinical Lipidology, 8, S47-S57. https://doi.org/10.1016/j.jacl.2014.02.011
Fattaccioli, V., Andraud, E., Gentil, M., French, S.W. and Rouach, H. (1999) Effects of Ethanol Administration on Rat Liver Protease Activities: Relationship with Oxidative Stress. Hepatology, 29, 14-20. https://doi.org/10.1002/hep.510290106
Athyros, V.G., Tziomalos, K., Gossios, T.D., Griva, T., Anagnostis, P., Kargiotis, K., et al. (2010) Safety and Efficacy of Long-Term Statin Treatment for Cardiovascular Events in Patients with Coronary Heart Disease and Abnormal Liver Tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREECE) Study: A Posthoc Analysis. Lancet, 376, 1916-1922. https://doi.org/10.1016/S0140-6736(10)61272-X
Lewis, J.H., Mortensen, M.E., Zweig, S., Fusco, M.J., Medoff, J.R. and Belder, R. (2007) Efficacy and Safety of High-Dose Pravastatin in Hypercholesterolemic Patients with Well-Compensated Chronic Liver Disease: Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Hepatology, 46, 1453-1463. https://doi.org/10.1002/hep.21848
Piton, A., Poynard, T., Imbert-Bismuth, F., Khalil, L., Delattre, J., Pelissier, E., et al. (1998) Factors Associated with Serum Alanine Transaminase Activity in Healthy Subjects: Consequences for the Definition of Average Values for Selecting Blood Donors, and Patients with Chronic hepatitis C. MULTIVIRC Group. Hepatology, 27, 1213-1219. https://doi.org/10.1002/hep.510270505
WagenKnecht, L.E., Scherzinger, A.L., Stamm, E.R., Hanley, A.J., Norris, J.M., Chen, Y.-D.I., et al. (2009) Correlates and Heritability of Non-Alcoholic Fatty Liver Disease in a Minority Cohort. Obesity, 17, 1240-1246. https://doi.org/10.1038/oby.2009.4
Del Ben, M., Polimeni, L., Carnevale, R., Bartimoccia, S., Nocella, C., Baratta, F., et al. (2014) NOX2-Generated Oxidative Stress Is Associated with the Severity of Ultrasound Liver Steatosis in Patients with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology, 14, Article No. 81. https://doi.org/10.1186/1471-230X-14-81
Schwimmer, J.B., Celedon, M.A., Lavine, J.E., Salem, R., Campbell, N., Schork, N.J., et al. (2009) Heritability of Non-Alcoholic Fatty Liver Disease. Gastroenterology, 136, 1585-1592. https://doi.org/10.1053/j.gastro.2009.01.050
Tanaka, K., Tokunaga, S., Kono, S., Tokudome, S., Akamatsu, T., Moriyama, T., et al. (1998) Coffee Consumtion and Decreased Serum Gamma-Glutamyltransferase and Aminotransferase Activities among Male Alcohol Drinkers. International Journal of Epidemiology, 27, 438-443. https://doi.org/10.1093/ije/27.3.438
Athyros, V.G., Mikhailidis, D.P., Didangelos, T.P., Giouleme, O.I., Liberopoulos, E.N., Karagiannis, A., et al. (2006) Effect of Multifactorial Treatment on Non-Alcoholic Fatty Liver Disease in Metabolic Syndrome: A Randomized Study. Current Medical Research and Opinion, 22, 873-883. https://doi.org/10.1185/030079906X104696
Wheeler, M.D., Kono, H., Yin, M., Nakagami, M., Uesugi, T., Arteel, G.E, et al. (2001) The Role of Kupffer Cell Oxidant Production in Early Ethanol-Induced Liver Disease. Free Radical Biology and Medicine, 31, 1544-1549. https://doi.org/10.1016/S0891-5849(01)00748-1
Foster, T., Budoff, M.J., Saab, S., Ahmadi, N., Gordon, C. and Guerci, AD. (2011) Atorvastatin and Antioxidants for Treating Non-Alcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial. American Journal of Gastroenterology, 106, 71-77. https://doi.org/10.1038/ajg.2010.299
Roglans, N., Verd, J.C., Peris, C., Alegret, M., Vazquez, M., Adzet, T., et al. (2002) High Doses of Atorvastatin and Simvastatin Impel Critical Enzymes Involved in VLDL Production. Lipids, 37, 445-454. https://doi.org/10.1007/s11745-002-0916-0
Aubert, J., Begriche, K., Knockaert, L., Robin, M.A. and Fromenty, B. (2011) Increased Expression of Cytochrome P450 2E1 in Non-Alcoholic Fatty Liver Disease: Mechanisms and Pathophysiological Role. Clinics and Research in Hepatology and Gastroenterology, 35, 630-637. https://doi.org/10.1016/j.clinre.2011.04.015
Wang, W., Zhao, C., Zhou, J., Zhen, Z., Wang, Y. and Shen, C. (2013) Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis. PLOS ONE, 8, e76538. https://doi.org/10.1371/journal.pone.0076538